We are live on ! Find out more
ALBO

Albireo Pharma Inc
ALBO

Delisted

ALBO was delisted on the 2nd of March, 2023.

Back to rankings

29 hedge funds and large institutions have $2.3M invested in Albireo Pharma Inc in 2016 Q1 according to their latest regulatory filings, with 1 funds opening new positions, 5 increasing their positions, 8 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

12% less funds holding

Funds holding: 33 → 29 (-4)

38% less repeat investments, than reductions

Existing positions increased: 5 | Existing positions reduced: 8

46% less capital invested

Capital invested by funds: $4.29M → $2.3M (-$1.99M)

80% less first-time investments, than exits

New positions opened: 1 | Existing positions closed: 5

Holders
29
Holders Change
-4
Holders Change %
-12.12%
% of All Funds
0.77%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
5
Reduced
8
Closed
5
Calls
$28K
Puts
–
Net Calls
+$28K
Net Calls Change
+$38K

Top Buyers

Rank Fund Capital Flow
1
Renaissance Technologies
Renaissance Technologies
New York
+$134K
2
Vanguard Group
Vanguard Group
Pennsylvania
+$101K
3
Deutsche Bank
Deutsche Bank
Germany
+$47.1K
4
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$4.89K
5
UBS Group
UBS Group
Switzerland
+$1.55K

Top Sellers

Rank Fund Capital Flow
1
Fidelity Investments
Fidelity Investments
Massachusetts
-$900K
2
BC
Broadfin Capital
New York
-$685K
3
SM
Sabby Management
Florida
-$333K
4
Nomura Holdings
Nomura Holdings
Japan
-$30K
5
Citadel Advisors
Citadel Advisors
Florida
-$14.7K
Name Holding Trade Value Shares
Change 		Change in
Stake
Citigroup
26
Citigroup
New York
– +$18 +2 New
1
2

ALBO Hedge Fund Activity: Q1 2016 in Review

29 of the 3,753 institutional investors tracked by Wall St. Rank reported a position in Albireo Pharma Inc (ALBO) for Q1 2016, worth a combined $2.3M — down 46% from $4.29M a quarter earlier.

Sellers outnumbered buyers: 5 funds closed out of ALBO and 1 opened new positions — a net loss of 4 holders — while 8 trimmed existing stakes and 5 added.

The largest buyer was Renaissance Technologies, adding an estimated $134K. The largest seller was Fidelity Investments, cutting an estimated $900K.

  • 29 institutional investors held Albireo Pharma Inc (ALBO) as of Q1 2016, down from 33 in Q4 2015.
  • Funds reported $2.3M of Albireo Pharma Inc stock for Q1 2016, down 46% quarter-over-quarter.
  • 1 fund opened new Albireo Pharma Inc positions in Q1 2016 and 5 closed out, a net change of -4 holders.
  • The largest Albireo Pharma Inc buyer in Q1 2016 was Renaissance Technologies, an estimated $134K added.
  • The largest Albireo Pharma Inc seller in Q1 2016 was Fidelity Investments, an estimated $900K sold.

Based on aggregated 13F filings for Q1 2016.